WILKES NSG 552 EXAM 1
PSYCHOPHARMACOLOGY – (2026) ACTUAL
QUESTIONS & ANSWERS (GUARANTEE
PASS)
Core Domains
• Foundational Neuroscience and Neurobiology
• Neurotransmitter Systems and Receptor Pharmacology
• Pharmacokinetics and Pharmacodynamics
• Cytochrome P450 Enzyme System and Drug Interactions
• Antidepressant Agents and Mood Stabilizers
• Antipsychotic Medications and Extrapyramidal Symptoms
• Anxiolytics, Hypnotics, and GABAergic Pharmacology
• Substance Use Disorder Pharmacotherapy
• Psychopharmacology Across the Lifespan
• Ethical and Legal Considerations in Prescribing
Introduction
The Wilkes NSG 552 Exam 1 Psychopharmacology assessment evaluates
graduate-level psychiatric-mental health nurse practitioner students' mastery
of foundational psychopharmacology principles essential for advanced clinical
practice. This comprehensive examination covers neuroanatomy,
neurotransmitter systems, receptor pharmacology, pharmacokinetics,
pharmacodynamics, and the pharmacological management of major
psychiatric disorders. The test bank employs multiple-choice and scenario-
based questions requiring applied clinical decision-making. Emphasis is placed
on understanding drug mechanisms, adverse effects, drug interactions, and
,evidence-based prescribing practices. Successful completion demonstrates
readiness to safely prescribe and manage psychotropic medications in diverse
patient populations.
SECTION ONE: QUESTIONS 1–100
Question 1
What is the definition of pharmacokinetics?
A. The study of what drugs do to the body
B. The study of what the body does to drugs
C. The study of drug-receptor binding
D. The study of drug efficacy
B. The study of what the body does to drugs
RATIONALE: Pharmacokinetics refers to absorption, distribution,
metabolism, and excretion (ADME) — what the body does to a drug.
Pharmacodynamics is what the drug does to the body.
Question 2
What is the definition of pharmacodynamics?
A. The study of drug metabolism in the liver
B. The study of drug excretion by the kidneys
C. The study of what drugs do to the body at target sites
D. The study of drug absorption in the GI tract
C. The study of what drugs do to the body at target sites
RATIONALE: Pharmacodynamics describes drug actions at receptors, ion
channels, enzymes, and carrier proteins/reuptake pumps.
Question 3
Which phase of pharmacokinetics involves the conversion of a drug into
metabolites, primarily in the liver?
A. Absorption
B. Distribution
,C. Metabolism
D. Excretion
C. Metabolism
RATIONALE: Metabolism (biotransformation) occurs mainly in the liver
via cytochrome P450 enzymes, converting drugs into more water-soluble
metabolites for excretion.
Question 4
The cytochrome P450 enzyme system is primarily responsible for which
pharmacokinetic process?
A. Drug absorption
B. Drug distribution
C. Drug metabolism
D. Drug excretion
C. Drug metabolism
RATIONALE: The CYP450 system in the liver is the major site of drug
metabolism. Inhibition or induction of these enzymes causes clinically
significant drug-drug interactions.
Question 5
A drug with high protein binding will have which characteristic?
A. Rapid onset of action
B. Reduced free (active) drug available
C. Increased renal excretion
D. Decreased half-life
B. Reduced free (active) drug available
RATIONALE: Highly protein-bound drugs remain bound to albumin and
are inactive. Only the unbound (free) fraction is pharmacologically active and
available for metabolism/excretion.
, Question 6
Which term describes the concentration of a drug required to produce 50% of
the maximum response?
A. Affinity
B. Efficacy
C. Potency (EC50)
D. Bioavailability
C. Potency (EC50)
RATIONALE: EC50 is the concentration producing 50% of maximal effect,
a measure of drug potency. Lower EC50 = higher potency.
Question 7
What is the primary difference between a drug's affinity and its efficacy?
A. Affinity is the strength of binding; efficacy is the ability to produce a
response
B. Affinity is the speed of onset; efficacy is the duration of action
C. Affinity is the drug's half-life; efficacy is its protein binding
D. Affinity and efficacy are synonymous
A. Affinity is the strength of binding; efficacy is the ability to produce a
response
RATIONALE: Affinity describes how tightly a drug binds to its receptor.
Efficacy (intrinsic activity) describes the magnitude of response the drug
produces once bound.
Question 8
A drug that binds to a receptor and produces a biological effect is called a(n):
A. Antagonist
B. Agonist
C. Inverse agonist
D. Allosteric modulator
PSYCHOPHARMACOLOGY – (2026) ACTUAL
QUESTIONS & ANSWERS (GUARANTEE
PASS)
Core Domains
• Foundational Neuroscience and Neurobiology
• Neurotransmitter Systems and Receptor Pharmacology
• Pharmacokinetics and Pharmacodynamics
• Cytochrome P450 Enzyme System and Drug Interactions
• Antidepressant Agents and Mood Stabilizers
• Antipsychotic Medications and Extrapyramidal Symptoms
• Anxiolytics, Hypnotics, and GABAergic Pharmacology
• Substance Use Disorder Pharmacotherapy
• Psychopharmacology Across the Lifespan
• Ethical and Legal Considerations in Prescribing
Introduction
The Wilkes NSG 552 Exam 1 Psychopharmacology assessment evaluates
graduate-level psychiatric-mental health nurse practitioner students' mastery
of foundational psychopharmacology principles essential for advanced clinical
practice. This comprehensive examination covers neuroanatomy,
neurotransmitter systems, receptor pharmacology, pharmacokinetics,
pharmacodynamics, and the pharmacological management of major
psychiatric disorders. The test bank employs multiple-choice and scenario-
based questions requiring applied clinical decision-making. Emphasis is placed
on understanding drug mechanisms, adverse effects, drug interactions, and
,evidence-based prescribing practices. Successful completion demonstrates
readiness to safely prescribe and manage psychotropic medications in diverse
patient populations.
SECTION ONE: QUESTIONS 1–100
Question 1
What is the definition of pharmacokinetics?
A. The study of what drugs do to the body
B. The study of what the body does to drugs
C. The study of drug-receptor binding
D. The study of drug efficacy
B. The study of what the body does to drugs
RATIONALE: Pharmacokinetics refers to absorption, distribution,
metabolism, and excretion (ADME) — what the body does to a drug.
Pharmacodynamics is what the drug does to the body.
Question 2
What is the definition of pharmacodynamics?
A. The study of drug metabolism in the liver
B. The study of drug excretion by the kidneys
C. The study of what drugs do to the body at target sites
D. The study of drug absorption in the GI tract
C. The study of what drugs do to the body at target sites
RATIONALE: Pharmacodynamics describes drug actions at receptors, ion
channels, enzymes, and carrier proteins/reuptake pumps.
Question 3
Which phase of pharmacokinetics involves the conversion of a drug into
metabolites, primarily in the liver?
A. Absorption
B. Distribution
,C. Metabolism
D. Excretion
C. Metabolism
RATIONALE: Metabolism (biotransformation) occurs mainly in the liver
via cytochrome P450 enzymes, converting drugs into more water-soluble
metabolites for excretion.
Question 4
The cytochrome P450 enzyme system is primarily responsible for which
pharmacokinetic process?
A. Drug absorption
B. Drug distribution
C. Drug metabolism
D. Drug excretion
C. Drug metabolism
RATIONALE: The CYP450 system in the liver is the major site of drug
metabolism. Inhibition or induction of these enzymes causes clinically
significant drug-drug interactions.
Question 5
A drug with high protein binding will have which characteristic?
A. Rapid onset of action
B. Reduced free (active) drug available
C. Increased renal excretion
D. Decreased half-life
B. Reduced free (active) drug available
RATIONALE: Highly protein-bound drugs remain bound to albumin and
are inactive. Only the unbound (free) fraction is pharmacologically active and
available for metabolism/excretion.
, Question 6
Which term describes the concentration of a drug required to produce 50% of
the maximum response?
A. Affinity
B. Efficacy
C. Potency (EC50)
D. Bioavailability
C. Potency (EC50)
RATIONALE: EC50 is the concentration producing 50% of maximal effect,
a measure of drug potency. Lower EC50 = higher potency.
Question 7
What is the primary difference between a drug's affinity and its efficacy?
A. Affinity is the strength of binding; efficacy is the ability to produce a
response
B. Affinity is the speed of onset; efficacy is the duration of action
C. Affinity is the drug's half-life; efficacy is its protein binding
D. Affinity and efficacy are synonymous
A. Affinity is the strength of binding; efficacy is the ability to produce a
response
RATIONALE: Affinity describes how tightly a drug binds to its receptor.
Efficacy (intrinsic activity) describes the magnitude of response the drug
produces once bound.
Question 8
A drug that binds to a receptor and produces a biological effect is called a(n):
A. Antagonist
B. Agonist
C. Inverse agonist
D. Allosteric modulator
